BACKGROUND/OBJECTIVES: Non-fermenting Gram-negative bacilli (NFGNB) represent a significant clinical challenge due to their intrinsic and acquired resistance, particularly in immunocompromised patients. Infections cause by NFGNB are associated with high morbidity and mortality, especially among patients with cystic fibrosis and hematologic malignancies. This study aimed to assess the in vitro susceptibility of clinically relevant NFGNB isolates to two newer antibiotics, cefiderocol and aztreonam/avibactam, and an established antibiotic, trimethoprim/sulfamethoxazole. METHODS: This retrospective, monocentric study analysed 94 NFGNB isolates (30 Pseudomonas aeruginosa, 30 Acinetobacter sp., 24 Stenotrophomonas maltophilia, and 10 Burkholderia cepacia complex). Susceptibility testing for cefiderocol, aztreonam/avibactam, and trimethoprim/sulfamethoxazole was conducted using gradient strip method. MIC values were interpreted using EUCAST breakpoints, ECOFFs, or alternative criteria when necessary. RESULTS: All S. maltophilia isolates were susceptible to cefiderocol (FCR) and aztreonam/avibactam (A/A) based on ECOFFs, with one strain resistant to trimethoprim-sulfamethoxazole (COT). Burkholderia cepacia complex strains also showed high susceptibility to FCR, with only one isolate exceeding the ECOFF for A/A, and 20% resistant to COT. All Acinetobacter sp. isolates were susceptible to FCR; however, most MIC values clustered at or just below the ECOFF value. In P. aeruginosa, one isolate was resistant to FCR, and three isolates (10%) were resistant to A/A. Interestingly, confirmed carbapenemase producers remained susceptible to both FCR and A/A. Most A/A MIC values for P. aeruginosa were just below the ECOFF. CONCLUSIONS: Cefiderocol and aztreonam/avibactam demonstrated promising in vitro activity against clinically relevant NFGNB, including carbapenem-resistant strains. These findings support their potential role as therapeutic options for difficult-to-treat infections, particularly in immunocompromised patients.

• Klíčová slova
• antimicrobial resistance, aztreonam/avibactam, cefiderocol, immunocompromised patients, non-fermenting gram-negative bacilli, susceptibility,
• Publikační typ
• časopisecké články MeSH

Non-fermentative Gram-negative bacilli are now one of the most important causes of severe infections in Polish hospitals. Acinetobacter species are serious concern because of the high prevalence of multi-drug resistance among strains. Resistance profiles for 53 Gram-negative non-fermentative blood isolates were done. MLST was carried out using 44 strains representing the most commonly isolated species: A. baumannii, P. aeruginosa, and S. maltophilia. MLST revealed that all 22 A. baumannii belonged to sequence type (ST) 2. The P. aeruginosa isolates belonged to 10 different STs. Four S. maltophilia isolates matched STs present in the database (ST4, ST15, ST116, ST142), seven isolates showing novel sequence types. Among P. aeruginosa and S. maltophilia PFGE confirmed the genetical variety of strains.

• Klíčová slova
• Bloodstream infection, MLST, Non-fermentative gram negative bacilli,
• MeSH
• antibakteriální látky farmakologie   MeSH
• bakteriemie mikrobiologie   MeSH
• fylogeneze MeSH
• gramnegativní bakterie klasifikace   účinky léků   genetika   izolace a purifikace   MeSH
• infekce spojené se zdravotní péčí krev   mikrobiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mikrobiální testy citlivosti MeSH
• multilokusová sekvenční typizace MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Polsko MeSH
• Názvy látek
• antibakteriální látky MeSH

Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia are considered emerging pathogens classified as a public health problem due to extensive antimicrobial resistance. Therefore, the discovery of new therapeutic strategies has become crucial. This study aimed to evaluate the antimicrobial activity of gallic acid and methyl gallate against non-fermenting bacteria. The study included five clinical isolates of Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia. The minimum inhibitory concentrations of gallic acid and methyl gallate were determined by the broth microdilution method. Growth curves, metabolic activity, and biofilm formation of each bacterial strain in the presence or absence of phenolic compounds were performed. Finally, the therapeutic efficacy of the compounds was evaluated using an in vivo model. Gallic acid and methyl gallate showed antibacterial activity against bacterial strains in a concentration range of 64 to 256 µg/mL, both compounds reduced bacterial growth and metabolic activity of the strains, even at subinhibitory concentrations. Only, methyl gallate exhibited activity to inhibit the formation of bacterial biofilms. Moreover, gallic acid and methyl gallate increased larval survival by up to 60% compared to 30% survival of untreated larvae in a bacterial infection model in Galleria mellonella. Our results highlight the potential of gallic acid and methyl gallate as therapeutic alternatives for infections by emerging non-fermentative bacteria.

• Klíčová slova
• Achromobacter xylosoxidans, Burkholderia cenocepacia, Stenotrophomonas maltophilia, Antimicrobial activity, Phenolic compounds,
• MeSH
• antibakteriální látky * farmakologie   MeSH
• biofilmy účinky léků   růst a vývoj   MeSH
• gramnegativní bakteriální infekce mikrobiologie   farmakoterapie   MeSH
• kyselina gallová * farmakologie   analogy a deriváty   MeSH
• larva mikrobiologie   MeSH
• lidé MeSH
• mikrobiální testy citlivosti MeSH
• můry mikrobiologie   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antibakteriální látky * MeSH
• kyselina gallová * MeSH
• methyl gallate MeSH Prohlížeč

Ertapenem is a broad-spectrum bactericidal carbapenem antibiotic. It differs from the other substances of this group by the absence of action against Gram-negative non-fermenting bacilli and by a long elimination half-life, which allows once-daily administration. It is administered once daily in a dose of 1 gram intravenously. Ertapenem is generally well-tolerated, with the most common side effects being diarrhea and phlebitis at the injection site. It is used for the treatment of community-acquired pneumonia, intra-abdominal and gynecological infections, and skin and soft tissue infections, including diabetic foot.

• MeSH
• antibakteriální látky aplikace a dávkování   škodlivé účinky   farmakokinetika   MeSH
• beta-laktamy aplikace a dávkování   škodlivé účinky   farmakologie   MeSH
• ertapenem MeSH
• lidé MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• antibakteriální látky MeSH
• beta-laktamy MeSH
• ertapenem MeSH